Skip to main content
Premium Trial:

Request an Annual Quote

Detroit R&D Receives $850K from NIH to Develop Recombinant Antibodies, Antibody Array

NEW YORK, Oct. 7 (GenomeWeb News) - Detroit R&D recently received a $100,000 Phase I Small Business Innovation Research award from the National Institutes of Health to fund the production of single-chain recombinant antibodies for early detection of cancer.


In addition, the company received a $750,000 Phase II SBIR award to develop antibody microarrays to screen drug-metabolizing enzymes.


Previously, Detroit R&D had received six SBIRs to develop technology for studying hypertension, COX-2-dependent DNA damage, and drug screening. In addition, the company currently has two active Phase I SBIRs in breast cancer and fetal alcohol syndrome and one active Phase II SBIR in drug metabolism of frog embryos.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.